Attributes | Values |
---|
rdf:type
| |
Description
| - Glioblastoma multiforme (GBM) is the most common, aggressive, and chemorefractory brain tumor in human adults. Notwithstanding significant discoveries in the elucidation of signaling pathways and genetics of GBM during the past 20 years there has been no breakthrough in the pharmacological treatment of this high-grade malignancy. We have previously demonstrated increased expression of βIII-tubulin in GBM asserting a link between aberrant expression of βIII-tubulin and a disruption of microtubule dynamics associated either with malignant tumor development de novo, or with malignant transformation of a low-grade glioma into GBM. This article reviews βIII-tubulin as a promising target in the experimental treatment of GBM and examines the potential use of epothilones, a new family of anticancer agents shown to be active in βIII-tubulin-expressing tumor cells.
- Glioblastoma multiforme (GBM) is the most common, aggressive, and chemorefractory brain tumor in human adults. Notwithstanding significant discoveries in the elucidation of signaling pathways and genetics of GBM during the past 20 years there has been no breakthrough in the pharmacological treatment of this high-grade malignancy. We have previously demonstrated increased expression of βIII-tubulin in GBM asserting a link between aberrant expression of βIII-tubulin and a disruption of microtubule dynamics associated either with malignant tumor development de novo, or with malignant transformation of a low-grade glioma into GBM. This article reviews βIII-tubulin as a promising target in the experimental treatment of GBM and examines the potential use of epothilones, a new family of anticancer agents shown to be active in βIII-tubulin-expressing tumor cells. (en)
|
Title
| - Targeting beta III-tubulin in glioblastoma multiforme: from cell biology and histopathology to cancer therapeutics
- Targeting beta III-tubulin in glioblastoma multiforme: from cell biology and histopathology to cancer therapeutics (en)
|
skos:prefLabel
| - Targeting beta III-tubulin in glioblastoma multiforme: from cell biology and histopathology to cancer therapeutics
- Targeting beta III-tubulin in glioblastoma multiforme: from cell biology and histopathology to cancer therapeutics (en)
|
skos:notation
| - RIV/68378050:_____/11:00378912!RIV13-GA0-68378050
|
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| - P(GAP302/10/1759), Z(AV0Z50520514)
|
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/68378050:_____/11:00378912
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - glioblastoma multiforme; tubulin binding agent; epothilones (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| |
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| - Anti-Cancer Agents in Medicinal Chemistry
|
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...vavai/riv/projekt
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| - Dráber, Pavel
- Katsetos, C. D.
- Kavallaris, M.
|
http://linked.open...ain/vavai/riv/wos
| |
http://linked.open...n/vavai/riv/zamer
| |
issn
| |
number of pages
| |